Archive for Werewolf

Born To Be Wild-Type: Unleashing the Power of Cytokines

January 19, 2022

Werewolf Therapeutics Added to the Nasdaq Biotechnology Index

December 16, 2021

Werewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting

December 2, 2021

Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 INDUKINE™ Program

August 19, 2021

Werewolf Therapeutics Announces Its Addition to the Russell 2000® Index

June 24, 2021

Werewolf Therapeutics Howls onto the Nasdaq with $120M IPO

April 30, 2021